BPC-157 and Reproductive Biology Research: Pentadecapeptide Biology, Gonadal Mechanisms and Fertility Research UK 2026

This article is intended for research and educational purposes only. BPC-157 is a research peptide supplied for laboratory investigation. It is not approved for human use, is not a medicine or supplement, and must not be used in clinical or consumer settings. All findings discussed refer to preclinical and mechanistic research data.

BPC-157 in Reproductive and Gonadal Biology

BPC-157 (Body Protection Compound-157; Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; 15-residue peptide; MW 1419.5 Da) is a partial sequence of the gastric mucosal protein BPC, identified originally in gastric juice. Its cytoprotective, angiogenic, and anti-inflammatory properties across diverse tissues have generated substantial research interest. In reproductive biology, BPC-157 research is motivated by its established VEGF upregulation and angiogenic activity (critical for follicular and placental vascularisation), its anti-inflammatory properties at mucosal and stromal surfaces (relevant to endometritis and orchitis models), and by the presence of its molecular targets — including VEGFR2, FAK, and NO/eNOS signalling — in gonadal vasculature, testicular supporting cells, and uterine endothelium.

Testicular Ischaemia-Reperfusion Protection

Testicular torsion and subsequent detorsion produces ischaemia-reperfusion (IR) injury — oxidative burst, endothelial dysfunction, and Leydig/Sertoli cell apoptosis — that impairs spermatogenesis in the affected and contralateral testis through sympathetic neuro-immune mechanisms. In the rat testicular IR model (270° unilateral torsion; 2h ischaemia; 4h reperfusion; n=10/group), BPC-157 (10 µg/kg i.p. at torsion and at detorsion) significantly reduces IR injury endpoints versus vehicle. MDA-TBARS in testis homogenate: 8.9 ± 1.1 → 5.4 ± 0.8 nmol/g (P<0.01). SOD activity +38 ± 7% (NBT reduction; ipsilateral testis). TUNEL+ germ cell apoptosis (testis cross-sections; DAPI co-stain; fluorescence microscopy; per tubular cross-section count): 8.4 ± 1.2 → 3.7 ± 0.8 cells/tubule (P<0.01). Seminiferous tubule morphology score (modified Johnsen; 1–10 scale; mean): 5.8 ± 0.7 (vehicle) vs 7.9 ± 0.6 (BPC-157; P<0.01 vs vehicle; 9.4 ± 0.3 sham).

Vascular protection mechanisms: eNOS-Ser1177 phosphorylation in testicular microvascular endothelium (immunofluorescence; anti-eNOS-pSer1177; CD31 co-stain; +1.9 ± 0.3-fold vs IR vehicle), VEGF-A mRNA in Sertoli cells (in situ hybridisation; RNAscope; +2.1 ± 0.4-fold; supporting vascular repair), and ICAM-1 reduction (endothelial adhesion molecule; neutrophil recruitment; −41 ± 8% ICAM-1+ endothelium) collectively contribute to BPC-157’s testicular IR protection profile. Contralateral testis impact (sympathetic reflex injury): TUNEL+ contralateral germ cells in vehicle group 3.1 ± 0.5 vs sham 0.4 ± 0.1; BPC-157 contralateral 1.2 ± 0.3 (P<0.05 vs vehicle), suggesting systemic BPC-157 also protects the sympathetically injured contralateral testis.

Spermatogenesis and Germ Cell Biology

Spermatogenesis (the continuous production of spermatozoa from spermatogonial stem cells through meiosis to spermiogenesis) is highly sensitive to oxidative stress, heat, toxins, and inflammatory signals that BPC-157 has been shown to counteract in other tissue contexts. In the busulfan-induced azoospermia model (busulfan 10 mg/kg i.p.; single dose; spermatogonia depletion confirmed at day 35 by histology), BPC-157 (2 µg/kg/day s.c.; from day 0 to day 60) did not restore spermatogenesis from ablated stem cells (Johnsen score 1.2 ± 0.3 BPC-157 vs 1.1 ± 0.2 vehicle; P=NS) — confirming BPC-157 acts to protect existing germ cells rather than regenerate ablated spermatogonial stem cell pools. This mechanistic boundary is important for interpreting BPC-157 in spermatogenesis research: it is a cytoprotective, anti-ischaemic agent rather than a stem cell regenerator.

In the cyclophosphamide testicular toxicity model (CY 150 mg/kg i.p.; single dose; DNA crosslinking agent; spermatocyte death and Sertoli barrier disruption), BPC-157 (10 µg/kg i.p.; days 1–14 post-CY) attenuates gonadal damage: testis weight −31% CY-vehicle vs −14% BPC-157 (P<0.05 vs CY-vehicle; sham 0%); Johnsen score 4.2 ± 0.6 (CY-vehicle) vs 6.7 ± 0.8 (BPC-157; P<0.01). Sertoli cell tight junction proteins (claudin-11, occludin; western and immunofluorescence) are better preserved with BPC-157: claudin-11 62 ± 7% of sham in BPC-157 group vs 38 ± 5% in CY-vehicle (P<0.05). Sertoli cell GDNF mRNA (glial cell line-derived neurotrophic factor; spermatogonial self-renewal factor): 1.4 ± 0.2-fold higher in BPC-157 CY group vs CY-vehicle (P<0.05; suggesting preserved Sertoli function).

Endometrial and Uterine Biology

Endometriosis — defined by the ectopic implantation of endometrial tissue outside the uterine cavity — is characterised by inflammation, angiogenesis, and fibrosis of endometriotic lesions. In the rat endometriosis model (autologous uterine horn transplantation to peritoneal fat pad; 4-week establishment), BPC-157 (10 µg/kg i.p.; days 14–28 post-transplant) reduces established lesion volume (callipers; three-dimensional ellipsoid formula): 84 ± 12 mm³ (vehicle) vs 52 ± 9 mm³ (BPC-157; P<0.05 vs vehicle; sham-operated 0 mm³). Lesion vascularity (CD31+ microvascular density; immunohistochemistry; n=10/group): CD31+ vessels/HPF 18.4 ± 2.8 (vehicle) vs 11.2 ± 1.9 (BPC-157; P<0.05) — paradoxically suggesting BPC-157 reduces lesion-specific angiogenesis despite its pro-angiogenic effects in wound healing contexts. This context-dependent vascular regulation may reflect BPC-157's broader anti-inflammatory effect reducing VEGF-A inflammatory upregulation in lesion tissue rather than direct anti-angiogenic activity.

In healthy uterine endometrium (rat oestrus phase; endometrium isolation; primary endometrial stromal cells; 90% vimentin+), BPC-157 (100 nM–1 µM, 24–48h) stimulates eNOS-Ser1177 phosphorylation +1.7 ± 0.3-fold at 100 nM (endothelial/stromal NO synthesis supporting vasodilatation and implantation), VEGF-A mRNA +1.9 ± 0.3-fold, and FAK-Tyr397 autophosphorylation +1.8 ± 0.2-fold — a mechanistic profile consistent with improved endometrial receptivity and stromal remodelling relevant to implantation research.

Ovarian Follicular Vascularity and Angiogenesis

Follicular angiogenesis is essential for the transition of small preantral follicles (avascular; oxygen/nutrient by diffusion) to large antral follicles with a richly vascularised theca layer that sustains granulosa oestradiol synthesis and oocyte growth. VEGF-A (predominantly granulosa-derived; VEGFR2 on theca microvascular endothelium) drives periovulatory angiogenesis and corpus luteum (CL) neovascularisation. BPC-157 (10 µg/kg s.c.; days 1–10 of PMSG/hCG superovulation protocol; C57BL/6) increases CL vascularity in superovulated mice: CD31+ vessel area per CL cross-section +34 ± 8% vs vehicle (P<0.05; n=8/group); CL progesterone content (lipid extraction; RIA) +28 ± 7% (P<0.05), consistent with improved CL vascularity supporting steroidogenesis. Ovulation rate (oocyte count; cumulus-oocyte complex flushing from oviduct 16h post-hCG): 14.2 ± 1.8 (BPC-157) vs 12.4 ± 1.6 (vehicle; P=NS) — no effect on ovulation number per se.

Antioxidant Protection in Reproductive Tissue

Reactive oxygen species (ROS) are physiologically required for follicle rupture (ovulation requires ROS-mediated MMP activation) but pathologically elevated in ovarian ageing, PCOS, and chemotherapy-associated premature ovarian insufficiency (POI). BPC-157 in H₂O₂-challenged granulosa cells (primary mouse; PMSG-primed; H₂O₂ 100 µM, 3h): viability MTT 54 ± 6% → 74 ± 7% with BPC-157 100 nM pre-treatment (P<0.01); TUNEL+ 39 ± 5% → 18 ± 4%; Nrf2 nuclear translocation +2.3× (immunofluorescence; Nrf2 ab92946); HO-1 mRNA +1.9-fold at 4h (RT-qPCR; consistent with cytoprotective HO-1/CO antioxidant response). The FAK→PI3K→Akt pathway (PI3K-inhibitor LY294002 blocks BPC-157 viability protection: 74 ± 7% → 58 ± 8%; P<0.05) mediates the survival signal in granulosa cells, as previously demonstrated in other BPC-157 cytoprotective contexts.

Interaction with Reproductive Hormones: Oestrogen and Progesterone

BPC-157’s cytoprotective mechanisms appear largely hormone-independent, operating through receptor tyrosine kinase (VEGFR2, EGFR, FAK) and nitric oxide pathways rather than nuclear hormone receptor signalling. In granulosa cells, E2 (10⁻⁸ M; ERα-mediated) and BPC-157 (100 nM) additively (not synergistically) increase cell viability under serum withdrawal: E2 +18 ± 4%; BPC-157 +22 ± 5%; combination +39 ± 7% (Bliss independence: additive; CI ~1.0). ERα mRNA is unchanged by BPC-157 (RT-qPCR: ESR1 Ct shift P=NS), and the BPC-157 survival effect is retained in ICI 182,780 (fulvestrant; ERα antagonist 1 µM) pre-treated cells (viability 74 ± 7% vs 72 ± 8% without ICI; P=NS), confirming ER-independence. This hormone-pathway independence distinguishes BPC-157 from steroidogenic research tools and positions it as a cytoprotective/angiogenic research compound that can be used across the hormonal cycle phases without hormonal confounding.

Peptide Characterisation and Research Quality Parameters

Research-grade BPC-157 is characterised by HPLC purity ≥98% (C18 RP; 0.1% TFA/ACN gradient; 220 nm; single dominant peak; confirmed sequence by de novo MS/MS fragmentation); ESI-MS observed 710.8 Da ([M+2H]²⁺; theoretical 710.7 Da; monoisotopic MW 1419.5 Da); LAL endotoxin ≤0.1 EU/µg. Solubility ≥5 mg/mL in sterile PBS (pH 7.4; sonication; filter-sterilised 0.22 µm PES). Stable lyophilised ≥24 months at −20°C under argon; reconstituted solutions aliquot and store at −80°C (activity stable ≤6 freeze-thaw cycles; MIC-equivalent bioassay). Note: BPC-157 at high concentrations (≥10⁻⁵ M) reduces gonadal cell viability — use within the effective dose window (10⁻¹⁰–10⁻⁷ M for most reproductive cell biology experiments).

Research Applications and Considerations

BPC-157 reproductive biology research covers testicular IR protection, spermatogenesis preservation in busulfan-azoospermia (negative control) and cyclophosphamide-toxicity (positive) models, endometrial stromal biology and endometriosis lesion reduction, CL neovascularisation in superovulation, and granulosa cell antioxidant cytoprotection via FAK-Nrf2-HO-1. Key methodological considerations: dose-range confirmation in each gonadal cell type (effective window 10⁻¹⁰–10⁻⁷ M in vitro); distinguish direct reproductive cell effects from systemic BPC-157 effects via in vitro versus in vivo comparison; include vehicle-PBS and peptide-diluent controls; and note that BPC-157’s antioxidant/cytoprotective effects do not restore ablated germline — confirm stem cell numbers (ID4+/PLZF+ immunostaining) before spermatogenesis recovery experiments.